Burning Rock Biotech Limited Q1 Loss Rises

Burning Rock Biotech (NASDAQ: BNR) reported Q2 2026 revenues of RMB134.7M (US$19.9M), down 9.3% YoY. Central lab revenue fell 10%, while in-hospital revenue rose 7.4%. Gross profit decreased 9.5% to RMB97.8M. The company expects new product approvals to drive future growth. Cash reserves stood at RMB419.1M as of June 30, 2026.

Burning Rock Biotech Ltd (BNR) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 Burning Rock Reports Second Quarter 2026 Financial Results GUANGZHOU, China, September 10, 2026—Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next-generation sequencing (NGS) technology in the fie

Polibeli Group Ltd (PLBL) furnished an SEC Form 6-K — earnings release. Polibeli Group Ltd Announces Unaudited Financial Results for the six months ended June 30, 2026 On September 21, 2026, Polibeli Group Ltd (the “Company”) announced its unaudited financial results for the six months ended June 30, 2026. Business and Strategic Update ● As of the da

Vicor Corporation's stock rose 12.3% after hours after raising its Q3 2026 revenue growth guidance from nearly 10% to over 20%, driven by royalties from its VPD licensing program. Four major companies have licensed the technology, and the CEO noted potential supply disruptions for unlicensed suppliers. The company also recently authorized a $150M share buyback and acquired properties for AI-driven demand. The Nasdaq closed at a record high, led by AI stocks, but broader indices were unchanged.

Optimum Communications, Inc. (OPTU) filed an SEC Form 8-K — Results of Operations and Financial Condition. Item 2.02 Results of Operations and Financial Condition. The information appearing below under Item 4.02 regarding certain previously reported financial information of Optimum Communications, Inc. (the "Company") for the fiscal year ended December 31, 2025, and the fiscal quarter

Abivax reported H1 2026 financials with €402.4M in cash and €767.1M from a July offering, extending runway to Q4 2029. Leadership changes include Chris Rabbat as CMO and Tim Kelly as CTO. The company repurchased royalty certificates for €76.5M, reducing debt. R&D expenses rose 38.5% YoY to €107.9M, driven by clinical trial progress and new indications for obefazimod.